Work

Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study

Year: 2023
Type: article
Study design: Clinical Trial
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: green
OpenAlex ID: W4388031558
FWCI: 3.597
Cites: 23
Cited by: 21
Related to: 10